Bluebird Bio Inc (BLUE) - News Archive

Bluebird bio, Inc. a biotechnology company focused on gene therapies, has successfully navigated the regulatory landscape to finalize its acquisition by Carlyle Group and SK Capital Partners. This merger, announced earl...

Bluebird Bio Reaffirms Commitment to Carlyle and SK Capital Amidst Unfulfilled Engagement with Ayrmid Ltd. Somerville, Mass. In a recent announcement, bluebird bio, Inc. (NASDAQ: BLUE) has confirmed that Ayrmid Ltd. has...

Bluebird Bio, Inc. (NASDAQ: BLUE), a biotechnology company known for its innovative approaches to gene therapy, recently announced a definitive agreement to be acquired by global investment firms Carlyle and SK Capital...

Gene Therapy Breakthrough Offers Hope for Beta-Thalassemia Patients SOMERVILLE, Mass. bluebird bio, Inc. (Nasdaq: BLUE) has announced promising long-term follow-up data indicating that betibeglogene autotemcel (commonly...

Transforming Healthcare Access: Bluebird Bio s Innovative Agreement with CMMI for Sickle Cell Gene Therapy In a significant stride towards enhancing healthcare accessibility, bluebird bio, Inc. (NASDAQ: BLUE), a leading...

bluebird bio Surges Ahead with Strong Q2 2024 Form 10-Q Filing and Record Inventory Turnover SOMERVILLE, Mass. bluebird bio, Inc. (Nasdaq: BLUE) has thrilling news to share: the successful completion of their Q2 2024 Fo...

A Chronicle of Progress in the Realm of Therapeutic Innovators: Bluebird Bio’s Recent Triumphs and Trials In the illustrious and often tumultuous arena of pharmaceutical advancements, the annals of bluebird bio, Inc. we...

bluebird bio Soars High: Completion of Q2 2024 Form 10-Q Filing and Robust Revenue Growth In the dynamic landscape of biotechnology, staying current with regulatory requirements and reporting significant financial miles...

Bluebird Bio s Strategic Restructuring: A Bold Move Towards ProfitabilityIn the ever-evolving landscape of biotechnology, where rapid advancements are often accompanied by substantial financial hurdles, bluebird bio, In...

Bluebird bio, Inc. (Nasdaq: BLUE) continues to navigate a landscape shaped by recent financial restatements and operational advancements. The company, a significant player in gene therapy, has faced scrutiny regarding i...

In a recent announcement, bluebird bio, Inc. (Nasdaq: BLUE) disclosed that it has received formal notices from The Nasdaq Stock Market LLC regarding its non-compliance with listing requirements. On August 20, 2024, Nasd...

In a significant announcement that underscores the challenges facing Bluebird Bio, Inc. (Nasdaq: BLUE), the company reported on August 20, 2024, that it has received formal notices from The Nasdaq Stock Market signaling...

SOMERVILLE, Mass. bluebird bio, Inc. (NASDAQ: BLUE) today announced its financial results for the second quarter, ending June 30, 2024, alongside significant developments in its commercial and operational activities. Th...

bluebird bio Strengthens Leadership Team with Appointment of O. James Sterling as Chief Financial Officer bluebird bio, Inc. (Nasdaq: BLUE), a pioneering gene therapy company, has announced the appointment of O. James S...

The renowned law firm of Kirby McInerney LLP has recently reminded investors of the looming May 28, 2024 deadline to assume the role of lead plaintiff in a federal securities class action. This legal action has been ini...

Blue Investor Alert: Kirby McInerney LLP Notifies Bluebird Bio, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit New York, NY Kirby McInerney LLP, a law firm renowned for its expertise in secur...

Bluebird Bio Faces Lawsuit Over Failure to Comply with Nasdaq Listing RuleOn May 28, 2024, the law firm of Kirby McInerney LLP announced the upcoming deadline for investors to seek the role of lead plaintiff in a federa...

CSIMarket.com is pleased to delve into the recent progress and achievements of Bluebird Bio, Inc. (NASDAQ: BLUE) (Bluebird), a notable company advancing the frontiers of commercial gene therapy. Bluebird has recently an...

Bluebird Bio Noncompliant with Nasdaq Rules as Annual Report Filing DelayedSomerville, Mass. - Bluebird Bio, Inc. (Nasdaq: BLUE) announced today that it has received a notice from The Nasdaq Stock Market LLC stating its...

Somerville, Mass. In a recent development, Bluebird Bio Inc. (Nasdaq: BLUE) confirmed that it has received a notice from The Nasdaq Stock Market LLC (Nasdaq) on April 24, 2024. The notice highlights that the Company is...